scholarly journals Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment

JGH Open ◽  
2019 ◽  
Vol 3 (4) ◽  
pp. 329-337 ◽  
Author(s):  
Koji Sawada ◽  
Yoshinori Saitho ◽  
Hidemi Hayashi ◽  
Takumu Hasebe ◽  
Shunsuke Nakajima ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Sorafenib Treatment

scholarly journals Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1206 ◽  
Author(s):  
Kenji Imai ◽  
Koji Takai ◽  
Takao Miwa ◽  
Daisuke Taguchi ◽  
Tatsunori Hanai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Fat Mass ◽  
Skeletal Muscle Mass ◽  
Subcutaneous Fat ◽  
Cox Proportional Hazards Model ◽  
Sorafenib Treatment ◽  
Skeletal Muscle Index ◽  
Fat Mass Index

The aim of this study was to investigate whether rapid depletions of fat mass and skeletal muscle mass predict mortality in hepatocellular carcinoma (HCC) patients treated with sorafenib. This retrospective study evaluated 61 HCC patients. The cross-sectional areas of visceral and subcutaneous fat mass and skeletal muscle mass were measured by computed tomography, from which the visceral fat mass index (VFMI), subcutaneous fat mass index (SFMI), and skeletal muscle index (L3SMI) were obtained. The relative changes in these indices per 120 days (ΔVFMI, ΔSFMI, and ΔL3SMI) before and after sorafenib treatment were calculated in each patient. Patients within the 20th percentile cutoffs for these indices were classified into the rapid depletion (RD) group. Kaplan–Meier analysis revealed that with respect to ΔL3SMI (p = 0.0101) and ΔSFMI (p = 0.0027), the RD group had a significantly poorer survival. Multivariate analysis using the Cox proportional-hazards model also demonstrated that ΔL3SMI (≤−5.73 vs. >−5.73; hazard ratio [HR]: 4.010, 95% confidence interval [CI]: 1.799–8.938, p = < 0.001) and ΔSFMI (≤−5.33 vs. >−5.33; HR: 4.109, 95% CI: 1.967–8.584, p = < 0.001) were independent predictors. Rapid depletions of subcutaneous fat mass and skeletal muscle mass after the introduction of sorafenib indicate a poor prognosis.

scholarly journals Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib

Liver Cancer ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. 193-206 ◽  
Author(s):  
Haruki Uojima ◽  
Makoto Chuma ◽  
Yoshiaki Tanaka ◽  
Hisashi Hidaka ◽  
Takahide Nakazawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Skeletal Muscle Mass

scholarly journals Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments

2020 ◽  
Vol 55 (10) ◽  
pp. 927-943 ◽  
Author(s):  
Giovanni Marasco ◽  
Matteo Serenari ◽  
Matteo Renzulli ◽  
Luigina Vanessa Alemanni ◽  
Benedetta Rossini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Appropriate Treatment ◽  
Risk Of Mortality ◽  
Short And Long Term ◽  
Poor Outcomes ◽  
And Function

Abstract Changes in body composition are associated with poor outcomes in cancer patients including hepatocellular carcinoma (HCC). Sarcopenia, defined as the loss of skeletal muscle mass, quality and function, has been associated with a higher rate of complications and recurrences in patients with cirrhosis and HCC. The assessment of patient general status before HCC treatment, including the presence of sarcopenia, is a key-point for achieving therapy tolerability and to avoid short- and long-term complications leading to poor patients’ survival. Thus, we aimed to review the current literature evaluating the role of sarcopenia assessment related to HCC treatments and to critically provide the clinicians with the most recent and valuable evidence. As a result, sarcopenia can be predictive of poor outcomes in patients undergoing liver resection, transplantation and systemic therapies, offering the chance to clinicians to improve the muscular status of these patients, especially those with high-grade sarcopenia at high risk of mortality. Further studies are needed to clarify the predictive value of sarcopenia in other HCC treatment settings and to evaluate its role as an additional staging tool for identifying the most appropriate treatment. Besides, interventional studies aiming at increasing the skeletal muscle mass for reducing complications and increasing the survival in patients with HCC are needed.

scholarly journals Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib

2020 ◽  
Vol 10 (16) ◽  
pp. 5403
Author(s):  
Yurika Kotoh ◽  
Issei Saeki ◽  
Takahiro Yamasaki ◽  
Ryo Sasaki ◽  
Norikazu Tanabe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Handgrip Strength ◽  
Significant Prognostic Factor ◽  
Skeletal Muscle Index ◽  
The Individual

Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as <26 and <18 kg and SMI <42 and SMI <38 cm2/m2 in men and women, respectively. Sarcopenia was defined as having low handgrip strength and muscle depletion. Multivariate analysis identified modified albumin–bilirubin grade 1–2a (p = 0.010), Barcelona Clinic Liver Cancer stage A–B (p = 0.011), and absence of low handgrip strength (p = 0.015) as favorable prognostic factors for survival. Furthermore, sarcopenia was an independent significant prognostic factor for survival. Time to treatment failure was associated with handgrip strength and sarcopenia. Our findings suggest that handgrip strength may be a useful marker of clinical outcomes in HCC patients treated with lenvatinib.

Total skeletal, psoas, and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 568-568
Author(s):  
Yu Yun Shao ◽  
Chih-Horng Wu ◽  
Po-Chin Liang ◽  
Chih-Hung Hsu ◽  
Tiffany Ting-Fang Shih
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Body Height ◽  
Rectus Abdominis ◽  
The Body ◽  
Advanced Hepatocellular Carcinoma ◽  
Disease Etiology ◽  
Sorafenib Treatment ◽  
Advanced Hcc

568 Background: We investigated whether low skeletal muscle mass (LSMM) defined according to different muscle groups on computed tomography (CT) scans could predict prognosis of advanced hepatocellular carcinoma (HCC). Methods: We analyzed patients who received first-line sorafenib treatment for advanced HCC in a prospective patient cohort between 2007 and 2012. The muscels areas of total skeletal muscle (TSM), paraspinal muscle (PS), psoas muscle (PM), rectus abdominis (RA), and abdominal wall (AW) were evaluated using a single CT slice at the third lumbar vertebra before treatment. LSMM was determined according to the TSM, PS, PM, RA and AW indices, which was calculated as the parameters divided by the square of the body height. Results: We enrolled 137 patients, with a mean age of 57.5 years; 120 were male and 17 were female. Liver disease etiology was hepatitis B virus in 94 (68.6%) patients and hepatitis C virus in 28 (20.4%) patients. All patients had Child–Pugh class A liver reserve. Women had significantly lower TSM index than men did ( p < .001). Among men, the optimal cut points of the TSM, PM and RA indices for LSMM diagnosis were 39.1, 8.3 and 2.9 cm2/m2, respectively. Patients with LSMM exhibited poorer overall survival than patients without LSMM, whether LSMM was defined by TSM index (median 5.1 vs. 8.0 months, p = 0.007), PM index (median 5.8 vs. 11.8 months, p < 0.001), or RA index (median 7.2 vs. 8.1 months, p = 0.003). After adjusting for clinical variables including underweight, age, tumor extent, and performance status, LSMM defined by TSM index (hazard ratio [HR]: 2.123, 95% confidence interval [CI]: 1.124-4.010, p = 0.020), PM index (HR: 1.855, 95% CI: 1.163-2.959, p = 0.009), or RA index (HR: 1.650, 95% CI: 1.004-2.710, p = 0.048) remained independent predictors for poor OS. Conclusions: LSMM defined by TSM, PM and RA indices are independent predictors for poor prognosis of advanced HCC, even after adjusted for body weight.

scholarly journals Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Liver Cancer ◽  
2017 ◽  
Vol 7 (1) ◽  
pp. 90-103 ◽  
Author(s):  
Ke-Vin Chang ◽  
Jin-De Chen ◽  
Wei-Ting Wu ◽  
Kuo-Chin Huang ◽  
Chia-Tzu Hsu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Tumor Recurrence ◽  
Skeletal Muscle Mass ◽  
Meta Analysis

scholarly journals Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Takamasa Kobayashi ◽  
Hirokazu Kawai ◽  
Oki Nakano ◽  
Satoshi Abe ◽  
Hiroteru Kamimura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Poor Prognosis ◽  
Skeletal Muscle Mass

scholarly journals Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma

JGH Open ◽  
2021 ◽  
Author(s):  
Shinji Itoh ◽  
Tomoharu Yoshizumi ◽  
Takahiro Tomiyama ◽  
Norifumi Iseda ◽  
Akinari Morinaga ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Hepatic Resection ◽  
Mass Loss ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Mass Loss
Sign in / Sign up

Export Citation Format

Share Document